Editorial: serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab

Aliment Pharmacol Ther. 2020 Sep;52(6):1080-1081. doi: 10.1111/apt.15987.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Azathioprine / therapeutic use
  • Crohn Disease* / drug therapy
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Infliximab / therapeutic use
  • Oncostatin M / therapeutic use

Substances

  • Gastrointestinal Agents
  • Oncostatin M
  • Infliximab
  • Azathioprine